Clinical Trial · NCT06421142

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

Overview

The aim of this trial is to investigate the value of FAPI PET/MRI, FDG PET/MRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients.

Sponsor

First Affiliated Hospital of Fujian Medical University

Phase

N/A

Contacts

Ning Xu, Doctor (CONTACT)

drxun@fjmu.edu.cn

13235907575

Xiao-Dong Li, Master (CONTACT)

lixiaodong@fjmu.edu.cn

15980273075

Xue-Yi Xue, Master (STUDY_CHAIR)

ClinicalTrials.gov

NCT06421142

Drug / Compound

FAPI

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Chelator: DOTA

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Completion of FAPI PET/MRI, FDG PET/MRI and MRI;
Patients with suspected muscle-invasive bladder cancer;
Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study
* Inclusion criteria for MIBC diagnostic studies
Complete clinical laboratory and pathological data.

Exclusion

Not receiving surgical treatment;
Combined with other malignant tumors;
* Exclusion criteria for MIBC diagnostic study
Previous allergy to contrast components or similar components;
Receiving neoadjuvant therapy before surgery;